Aura Biosciences, Inc. (NASDAQ:AURA – Free Report) – Stock analysts at HC Wainwright lifted their FY2026 earnings per share (EPS) estimates for shares of Aura Biosciences in a research note issued on Sunday, November 8th. HC Wainwright analyst A. Maldonado now expects that the company will post earnings per share of ($1.50) for the year, up from their previous forecast of ($1.71). HC Wainwright currently has a “Buy” rating and a $18.00 price objective on the stock. The consensus estimate for Aura Biosciences’ current full-year earnings is ($1.61) per share. HC Wainwright also issued estimates for Aura Biosciences’ Q4 2026 earnings at ($0.29) EPS, Q1 2027 earnings at ($0.30) EPS, Q2 2027 earnings at ($0.30) EPS, Q3 2027 earnings at ($0.31) EPS, Q4 2027 earnings at ($0.31) EPS, FY2027 earnings at ($1.23) EPS, FY2028 earnings at ($1.07) EPS, FY2029 earnings at $0.01 EPS and FY2030 earnings at $0.76 EPS.
Aura Biosciences (NASDAQ:AURA – Get Free Report) last issued its quarterly earnings results on Monday, November 9th. The company reported ($0.29) EPS for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.08.
AURA has been the topic of several other research reports. Wall Street Zen cut Aura Biosciences from a “hold” rating to a “sell” rating in a research note on Sunday, August 16th. Citigroup reaffirmed a “market outperform” rating on shares of Aura Biosciences in a research report on Tuesday. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Aura Biosciences in a research note on Monday, October 12th. Three analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, Aura Biosciences has a consensus rating of “Moderate Buy” and a consensus target price of $17.50.
View Our Latest Report on Aura Biosciences
Aura Biosciences Trading Down 0.1%
NASDAQ:AURA opened at $7.65 on Wednesday. Aura Biosciences has a 52-week low of $4.73 and a 52-week high of $9.53. The stock has a 50-day simple moving average of $6.55 and a 200 day simple moving average of $6.74.
Hedge Funds Weigh In On Aura Biosciences
A number of large investors have recently modified their holdings of the business. HighTower Advisors LLC bought a new position in shares of Aura Biosciences in the 3rd quarter valued at about $110,000. Russell Investments Group Ltd. raised its holdings in Aura Biosciences by 203.6% during the third quarter. Russell Investments Group Ltd. now owns 54,618 shares of the company’s stock worth $343,000 after acquiring an additional 36,628 shares in the last quarter. Parallel Advisors LLC raised its holdings in Aura Biosciences by 74.0% during the third quarter. Parallel Advisors LLC now owns 9,857 shares of the company’s stock worth $62,000 after acquiring an additional 4,192 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. bought a new stake in Aura Biosciences during the third quarter worth about $33,000. Finally, Profund Advisors LLC bought a new stake in Aura Biosciences during the third quarter worth about $94,000. 96.75% of the stock is currently owned by institutional investors and hedge funds.
Key Aura Biosciences News
Here are the key news stories impacting Aura Biosciences this week:
- Positive Sentiment: Aura reported third-quarter 2026 EPS of ($0.29), a narrower loss than the $0.37 analysts expected. The results were linked to a prior share-price rally. Aura Biosciences Reports Third Quarter 2026 Financial Results and Recent Business Highlights
- Positive Sentiment: HC Wainwright raised its EPS estimates across 2026–2030, including improving its 2027 forecast to a loss of $1.23 per share from $1.63 and its 2029 outlook from a loss to a small profit. The firm reiterated its Buy rating and $18 price target. The revisions suggest the analyst sees a stronger earnings trajectory, though profitability remains a longer-term prospect.
- Positive Sentiment: The company advanced its Phase 3 eye-cancer trial and said its cash runway extends into 2029, offering additional time to pursue development without near-term funding pressure. Aura Biosciences Advances Phase 3 Eye Cancer Trial; Cash Runway Extends Into 2029
Aura Biosciences Company Profile
Aura Biosciences is a clinical-stage biotechnology company developing treatments for cancer, with a focus on therapies designed to selectively destroy tumor cells while limiting damage to surrounding healthy tissue. The company is headquartered in the Boston area. Its lead candidate, belzupacap sarotalocan (formerly AU-011), is an investigational therapy being studied for choroidal melanoma, a cancer that develops in the eye. It uses a virus-like particle linked to a light-activated compound; after the compound binds to tumor cells, near-infrared light activates it to damage those cells.
Featured Stories
- Five stocks we like better than Aura Biosciences
- Poll Reveals: Which States Are Most Prepared for a Crisis? [2026]
- Why Kinder Morgan’s Chairman Just Bought $15 Million in Stock
- Rocket Lab’s Record Backlog Could Fuel a Rebound, But Neutron Raises the Stakes
- Don’t Let Their Low Yields Fool You: 3 Dividend Stocks Worth Watching
Receive News & Ratings for Aura Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aura Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
